295 related articles for article (PubMed ID: 33538790)
1. Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men: Results from the MALE Phase 2 Randomized Clinical Trial.
Reinisch M; Seiler S; Hauzenberger T; Kamischke A; Schmatloch S; Strittmatter HJ; Zahm DM; Thode C; Furlanetto J; Strik D; Möbus V; Reimer T; Sinn BV; Stickeler E; Marmé F; Janni W; Schmidt M; Rudlowski C; Untch M; Nekljudova V; Loibl S
JAMA Oncol; 2021 Apr; 7(4):565-572. PubMed ID: 33538790
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; ;
N Engl J Med; 2014 Jul; 371(2):107-18. PubMed ID: 24881463
[TBL] [Abstract][Full Text] [Related]
3. A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy.
Le Rhun E; Delbeuck X; Lefeuvre-Plesse C; Kramar A; Skrobala E; Pasquier F; Bonneterre J
Breast Cancer Res Treat; 2015 Aug; 152(3):569-80. PubMed ID: 26160250
[TBL] [Abstract][Full Text] [Related]
4. Effects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial.
Zong X; Yu Y; Yang H; Chen W; Ding X; Liu S; Li X; Chen X; Jiang C; Xia X; Huang R; Zhu M; Hu J; Liang C
JAMA Oncol; 2022 Feb; 8(2):252-258. PubMed ID: 34967844
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
6. Ovarian Function Recovery During Anastrozole in Breast Cancer Patients With Chemotherapy-Induced Ovarian Function Failure.
van Hellemond IEG; Vriens IJH; Peer PGM; Swinkels ACP; Smorenburg CH; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; Kitzen JJEM; de Boer M; de Roos WK; Linn SC; Imholz ALT; Tjan-Heijnen VCG;
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29546343
[TBL] [Abstract][Full Text] [Related]
7. [Adjuvant endocrine therapy in breast cancer].
Huober J; Thürlimann B
Ther Umsch; 2008 Apr; 65(4):193-200. PubMed ID: 18622910
[TBL] [Abstract][Full Text] [Related]
8. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study.
Ellis MJ; Gao F; Dehdashti F; Jeffe DB; Marcom PK; Carey LA; Dickler MN; Silverman P; Fleming GF; Kommareddy A; Jamalabadi-Majidi S; Crowder R; Siegel BA
JAMA; 2009 Aug; 302(7):774-80. PubMed ID: 19690310
[TBL] [Abstract][Full Text] [Related]
9. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
[TBL] [Abstract][Full Text] [Related]
10. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Melisko ME; Goldman ME; Hwang J; De Luca A; Fang S; Esserman LJ; Chien AJ; Park JW; Rugo HS
JAMA Oncol; 2017 Mar; 3(3):313-319. PubMed ID: 27832260
[TBL] [Abstract][Full Text] [Related]
11. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.
Bachelot T; Bourgier C; Cropet C; Ray-Coquard I; Ferrero JM; Freyer G; Abadie-Lacourtoisie S; Eymard JC; Debled M; Spaëth D; Legouffe E; Allouache D; El Kouri C; Pujade-Lauraine E
J Clin Oncol; 2012 Aug; 30(22):2718-24. PubMed ID: 22565002
[TBL] [Abstract][Full Text] [Related]
13. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist (GnRHa) among estrogen receptor (ER)-positive premenopausal breast cancer patients: effects on ovarian function, disease-free survival, and overall survival.
Zhang Y; Ji Y; Li J; Lei L; Wu S; Zuo W; Jia X; Wang Y; Mo M; Zhang N; Shen Z; Wu J; Shao Z; Liu G
Breast Cancer Res Treat; 2018 Apr; 168(3):679-686. PubMed ID: 29332135
[TBL] [Abstract][Full Text] [Related]
14. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial.
Del Mastro L; Boni L; Michelotti A; Gamucci T; Olmeo N; Gori S; Giordano M; Garrone O; Pronzato P; Bighin C; Levaggi A; Giraudi S; Cresti N; Magnolfi E; Scotto T; Vecchio C; Venturini M
JAMA; 2011 Jul; 306(3):269-76. PubMed ID: 21771987
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh S; Romond E; Black EP; Van Meter E; Shelton B; Kadamyan-Melkumian V; Stevens M; Elledge R
Breast Cancer Res Treat; 2014 Jan; 143(2):325-32. PubMed ID: 24327334
[TBL] [Abstract][Full Text] [Related]
16. Effect of Fractional Carbon Dioxide vs Sham Laser on Sexual Function in Survivors of Breast Cancer Receiving Aromatase Inhibitors for Genitourinary Syndrome of Menopause: The LIGHT Randomized Clinical Trial.
Mension E; Alonso I; Anglès-Acedo S; Ros C; Otero J; Villarino Á; Farré R; Saco A; Vega N; Castrejón N; Ordi J; Rakislova N; Tortajada M; Matas I; Gómez S; Ribera L; Castelo-Branco C
JAMA Netw Open; 2023 Feb; 6(2):e2255697. PubMed ID: 36763359
[TBL] [Abstract][Full Text] [Related]
17. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients.
Eggemann H; Ignatov A; Smith BJ; Altmann U; von Minckwitz G; Röhl FW; Jahn M; Costa SD
Breast Cancer Res Treat; 2013 Jan; 137(2):465-70. PubMed ID: 23224235
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
[TBL] [Abstract][Full Text] [Related]
20. Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors.
Suh KJ; Kim SH; Lee KH; Kim TY; Kim YJ; Han SW; Kang E; Kim EK; Kim K; No JH; Han W; Noh DY; Lee M; Kim HS; Im SA; Kim JH
Cancer Res Treat; 2017 Oct; 49(4):1153-1163. PubMed ID: 28253566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
